Larvol Delta - A2-Biotherapeutics-Presents-Early-Safety-and-Efcacy-Data-from-the-DENALI1-Study-of-A2B395-Highlighting-First-Reported-Case-of-Complete-Response-to-CAR-TCell-Therapy-in-Anal-Cancer-and-Partial-Response-at-6-Months-in-Refractory-Head-amp-Neck-Cancer

A2B395 - A2 Biotherap

https://www.businesswire.com/news/home/20260913289621/en/A2-Biotherapeutics-Presents-Early-Safety-and-Efficacy-Data-from-the-DENALI-1-Study-of-A2B395-Highlighting-First-Reported-Case-of-Complete-Response-to-CAR-T-Cell-Therapy-in-Anal-Cancer-and-Partial-Response-at-6-Months-in-Refractory-Head-Neck-Cancer

Sep 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Next